Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 11, 2016 07:30 ET | Source: Pluristem Therapeutics Inc.

Pluristem Advances its U.S. FDA Trial in Hematologic Indication

Enters into an agreement with a global drug development services company (CRO)Trial was cleared by U.S. FDA earlier this yearData could support use of Pluristem’s PLX-R18 in a broad range hematologic...
June 22, 2016 03:00 ET | Source: Pluristem Therapeutics Inc.

Pluristem Reports Data Showing PLX-PAD Cells Effective in Treating Duchenne Muscular Dystrophy

PLX-PAD cells increase regeneration of muscle tissue and reduce inflammation and cell deathPluristem donated cells for the studies performed in conjunction with ADI- the Association Duchenne Israel ...
May 16, 2016 03:00 ET | Source: Pluri Inc.

Pluristem Completes Enrollment of 150 Patients in Phase II Intermittent Claudication Trial

Trial expands to randomize 20 more patients to receive two injections per patientData release on track for 2017HAIFA, Israel, May 16, 2016 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc....
May 10, 2016 03:00 ET | Source: Pluri Inc.

Pluristem Reports Third Quarter Fiscal 2016 Financial Highlights and Clinical Development Update

HAIFA, Israel, May 10, 2016 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today reported financial...
May 09, 2016 05:00 ET | Source: Pluri Inc.

Pluristem Awarded $3.3 Million Grant by Israeli Government

HAIFA, Israel, May 09, 2016 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today announced that its wholly...
April 21, 2016 04:00 ET | Source: Pluri Inc.

Pluristem Enters into Licensing Agreement with TES Holdings Co., Ltd., a venture company derived from the University of Tokyo, to Acquire Rights for Placental Cell Therapy Patent for Variety of Ischemic Conditions including Heart Disease and Stroke

HAIFA, Israel, April 21, 2016 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-derived cell therapy products, today announced that it has...
April 13, 2016 03:00 ET | Source: Pluri Inc.

Pluristem Continues to Strengthen its Position in Japan – Granted Two Key Cell Therapy Patents

HAIFA, Israel, April 13, 2016 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today announced that the Japan...
February 16, 2016 08:00 ET | Source: Pluri Inc.

National Institutes of Health’s NIAID Initiating Dose Evaluation Studies in Animal Models of Pluristem’s PLX-R18 in the Treatment of Acute Radiation Syndrome

HAIFA, Israel, Feb. 16, 2016 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today announced that the...
February 10, 2016 08:00 ET | Source: Pluri Inc.

Pluristem Reports Second Quarter Fiscal 2016 Financial Highlights and Clinical Development Update

HAIFA, Israel, Feb. 10, 2016 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today reported financial...
January 26, 2016 03:00 ET | Source: Pluri Inc.

Pluristem to Present at Bio CEO & Investor Conference in New York City on February 8, 2016

HAIFA, Israel, Jan. 26, 2016 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today announced that Dr. Karine...